Text Size

Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia

This study is not yet open for participant recruitment.
Verified January 2012 by National Cancer Institute (NCI)
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01505699
First received: January 4, 2012
Last updated: NA
Last verified: January 2012
History: No changes posted

January 4, 2012
January 4, 2012
March 2012
March 2013   (final data collection date for primary outcome measure)
  • Comprehensive view of microRNA expression by cytogenetic subgroup [ Designated as safety issue: No ]
  • MicroRNA expression in relation to clinical outcome [ Designated as safety issue: No ]
  • Differential microRNA expression between normal B-cells and progenitors compared to B-ALL [ Designated as safety issue: No ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia
Micro RNA Expression Analysis in B-Lineage Adult Acute Lymphoblastic Leukemia From ALL Trial, E2993, Including Patients With Various Cytogenetic and Molecular Abnormalities

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.

PURPOSE: This research study is studying biomarkers in samples from patients with acute lymphoblastic leukemia enrolled on ECOG-2993 clinical trial.

OBJECTIVES:

  • To identify microRNAs that behave as oncogenes or as tumor suppressor genes in B-lineage acute lymphoblastic leukemia (ALL) in vitro and in vivo.
  • To examine if single microRNA or signatures of microRNA correspond to different clinical outcomes in cytogenetically distinct B-ALL groups.

OUTLINE: RNA from archived samples are analyzed for microRNA expression profile in vitro and in vivo.
Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Leukemia
  • Genetic: RNA analysis
  • Genetic: cytogenetic analysis
  • Genetic: microarray analysis
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
186
Not Provided
March 2013   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Samples from patients enrolled on ECOG-2993
  • Samples from patients with recurrent cytogenetic abnormalities other than BCR-ABL, including MLL/AF4, E2A/PBX1, and TEL/AML1

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Both
15 Years to 65 Years
No
Not Provided
Not Provided
 
NCT01505699
CDR0000720304, ECOG-E2993T4
Not Provided
Robert L. Comis, ECOG Group Chair's Office
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Hans-Guido Wendel, MD Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP